Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

Cancer

Volumn 118, Issue 2, 2012, Pages 418-427

  Cortes, Jorge ^a   Kantarjian, Hagop ^a   Ball, Edward D ^b   DiPersio, John ^c   Kolitz, Jonathan E ^d   Fernandez, Hugo F ^e   Goodman, Mark ^e   Borthakur, Gautam ^a   Baer, Maria R ^f,g   Wetzler, Meir ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Antisense; Cenersen; p53; Refractory; Relapsed

Indexed keywords

ANTIOXIDANT; CENERSEN; CYTARABINE; IDARUBICIN; PARACETAMOL;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; BLEEDING; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAIR LOSS; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INDUCED HYPOTHERMIA; INSOMNIA; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL EDEMA; PETECHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GENES, P53; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RECURRENCE; TREATMENT FAILURE;

EID: 84855507072     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26292     Document Type: Article

References (40)

1. Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008;15:959-976. (Pubitemid 351712601)
2. Asker C, Wiman KG, Selivanova G. p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun. 1999;265:1-6.
3. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277-288. (Pubitemid 37328781)
4. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1:289-298. (Pubitemid 41039153)
5. Schmitt CA. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer. 2003;3:286-295. (Pubitemid 37328864)
6. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57:4285-4300. (Pubitemid 27413438)
7. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006;103:1888-1893. (Pubitemid 43228788)
8. Kim E, Deppert W. Interactions of mutant p53 with DNA: guilt by association. Oncogene. 2007;26:2185-2190. (Pubitemid 46536649)
9. Li Y, Guessous F, Kwon S, et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res. 2008;68:1723-1731. (Pubitemid 351416557)
10. Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor- H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 2006;66:6319-6326.
11. Yang X, Pater A, Tang S-C. Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumorderived p53 mutants. Oncogene. 1999;18:4546-4553. (Pubitemid 29405886)
12. Girnita L, Girnita A, Brodin B, et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 2000;60:5278-5283.
13. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404:42-49. (Pubitemid 30143125)
14. Sharp JG, Bishop MR, Copple B, et al. Oligonucleotide enhanced cytotoxicity of idarubicin for lymphoma cells. Leuk Lymphoma. 2001;42:417-427. (Pubitemid 32725598)
15. Bayever E, Haines KM, Iversen PL, et al. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma. 1994;12:223-231. (Pubitemid 24077171)
16. Papaphilis AD, Kamper EF, Grammenou S, Kattamis C, Pangalis GA. RNase H of human leukemic cells: a new biological parameter in the study of human leukemias. Anticancer Res. 1990;10:1201-1212. (Pubitemid 20359204)
17. Papaphilis AD, Kamper EF, Grammenou S, Kattamis C, Pangalis GA. A new mononuclear cell (MNC) RNase H activity-based parameter (f) with possible prognostic value in assessing progression in acute myeloid leukaemia. Leuk Lymphoma. 1990;1:209-220. (Pubitemid 20268702)
18. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756. (Pubitemid 26240412)
19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC aml 10 trial. Blood. 1998;92:2322-2333. (Pubitemid 28452973)
20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649. (Pubitemid 46594039)
21. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol. 1996;14:1320-1326. (Pubitemid 26105542)
22. Fan S, Smith ML, Rivet DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995;55:1649-1654.
23. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p2l. Nature. 1996;381:713-716. (Pubitemid 26196573)
24. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996;88:956-965.
25. Sak A, Wurm R, Elo B, et al. Increased radiation-induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligodeoxynucleotides targeting p53 and p21WAF1/CIP1. Cancer Gene Ther. 2003;10:926-934. (Pubitemid 37532339)
26. Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110:3547-3551. (Pubitemid 350159619)
27. Nagai F, Hiyoshi Y, Sugimachi K, Tamura H-o. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull. 2002;25:383-385. (Pubitemid 39663295)
28. Krovat BC, Tracy JH, Omiecinski CJ. Fingerprinting of cytochrome P450 and microsomal epoxide hydrolase gene expression in human blood cells. Toxicol Sci. 2000;55:352-360. (Pubitemid 30353243)
29. Rogers LK, Smith CV. Acetaminophen (AP) at therapeutic doses (for humans) convalently binds to DNA in mice. The Toxicologist. 1996;30:282. Abstract 1446.
30. Eleos Internal Report. ELR1025b study: MALDI-TOF investigation of drug-drug covalent reaction between cenersen phosphorothioate DNA and the phosphodiester congener with NAPQI in both pH 3 phosphate buffer and pH 7 phosphate buffer containing 0.1 mM cysteine. 2007.
31. 1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res. 1998;4:1055-1064.
32. Waf1/Cip1- modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E. Neoplasia. 1999;1:544-556.
33. waf1/cip1 in normal human fibroblasts. Eur J Biochem. 2000;267:2290-2296.
34. Waf1 in green tea polyphenol-induced growth arrest and apoptosis of oral carcinoma cells. Anticancer Res. 2005;25:63-67.
35. Waf1/Cip1 expression: involvement of p38 mitogen-activated protein kinase. Biochem Pharmacol. 2005;69:1815-1827.
36. Eleos Internal Report. ELP1020 study: historical investigation of response rate. 2009.
37. Pritchard DM, Potten CS, Hickman JA. The relationship between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res. 1998;58:5453-5465. (Pubitemid 28551130)
38. Wlodarski P, Wasik M, Ratajczak MZ, et al. Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood. 1998;91:2998-3006. (Pubitemid 28227552)
39. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999;285:1733-1737. (Pubitemid 29428873)
40. Botchkarev VA, Komarova EA, Siebenhaar F, et al. p53 is essential for chemotherapy-induced hair loss. Cancer Res. 2000;60:5002-5006.